Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer

American Journal of Cancer Research

Tae Soo Kim¹  Kyu Hyun Park¹  Won Suk Lee¹  Jeong Min Kim¹  Myung Eun Lee¹  Hyun Cheol Chung¹  Sun Young Rha¹  Choong-Kun Lee¹  Joong Bae Ahn¹  Kang Young Lee¹ 

关键词: Colorectal cancer;    FGFR;    KRAS;    BRAF;    Dovitinib (TKI258);    multi-target angiokinase inhibitor;   

DOI  :  

学科分类：肿瘤学

来源: e-Century Publishing Corporation

【 授权许可】

Unknown